In Brief
To address the identity of castrationresistant prostate cells in vivo, BarrosSilva et al. coupled single-cell analysis with organoid culture and in situ lineage tracing. They identify LY6D as a progenitor marker that liaises intrinsically castration-resistant luminal cells and castration-resistant prostate tumor growth. 
CASTRATED

SUMMARY
The exact identity of castrate-resistant (CR) cells and their relation to CR prostate cancer (CRPC) is unresolved. We use single-cell gene profiling to analyze the molecular heterogeneity in basal and luminal compartments. Within the luminal compartment, we identify a subset of cells intrinsically resistant to castration with a bi-lineage gene expression pattern. We discover LY6D as a marker of CR prostate progenitors with multipotent differentiation and enriched organoid-forming capacity. Lineage tracing further reveals that LY6D + CR luminal cells can produce LY6D
À luminal cells. In contrast, in luminal cells lacking PTEN, LY6D + cells predominantly give rise to LY6D + tumor cells, contributing to high-grade PIN lesions. Gene expression analyses in patients' biopsies indicate that LY6D expression correlates with early disease progression, including progression to CRPC. Our studies thus identify a subpopulation of luminal progenitors characterized by LY6D expression and intrinsic castration resistance. LY6D may serve as a prognostic maker for advanced prostate cancer.
INTRODUCTION
Prostate cancer (PCa) remains the second most lethal malignancy among Western men (Siegel et al., 2014) and is treated mainly with androgen deprivation therapy (ADT). Although therapy is initially effective, most patients inevitably progress to castration-resistant PCa (CRPC). Such patients may benefit from new-generation drugs targeting the androgen receptor (AR) axis (e.g., enzalutamide and abiraterone) (de Bono et al., 2011; Scher et al., 2012) . However, therapeutic options for CRPC remain largely limited (Watson et al., 2015) . Two models have been proposed to explain the mechanism of castration resistance (Isaacs, 2008; Shen and Abate-Shen, 2010) . The prevailing model posits that androgen-dependent cancer cells adapt to ADT by acquiring castration-resistant (CR) properties through genetic/epigenetic changes. Alternatively, a subset of PCa cells may be intrinsically CR and are selected for growth following ADT.
The prostate gland is composed of basal and luminal epithelial cells (of note, these are positional terms and do not fully reflect the cellular subtypes), as well as rare neuroendocrine cells (Shen and Abate-Shen, 2010) . Unlike basal cells, which are largely insensitive to androgen deprivation (Bauman et al., 2014; Isaacs, 2008; Lin-Tsai et al., 2014) , the majority of luminal cells undergo apoptosis during castration, although a small proportion remains CR (Rane et al., 2014; Wang and Shen, 2011) . Prostate basal cells possess multipotent stem cell activity and can differentiate into luminal cells and serve as a cell-of-origin of PCa, as revealed by transplantation Lawson et al., 2010) and injury repair (Kwon et al., 2014; Toivanen et al., 2016) assays. However, lineage-tracing studies using inducible luminal-specific mouse models, such as Nkx3.1-CreER (Wang et al., 2009) , PSA-CreER (Liu et al., 2011) , and K8-CreER (Choi et al., 2012; Ousset et al., 2012) , demonstrate that the prostate luminal lineage in adults is largely self-sustained by luminal cells. In particular, these studies support the existence of CR multipotent and unipotent luminal progenitor (LP) cells that repopulate the luminal lineage upon androgen-induced regeneration (Choi et al., 2012; Ousset et al., 2012; Wang et al., 2009 Wang et al., , 2013 Wang et al., , 2014 . Lineage-tracing experiments reveal that PCa may have a basal origin; however, luminal cells have been shown as the preferred cell-of-origin (Choi et al., 2012; Ousset et al., 2012; Wang et al., 2009 Wang et al., , 2013 Wang et al., , 2014 . Moreover, the recently developed organoid system has allowed detection of multipotent or unipotent LPs in vitro from both human and mouse origins (Agarwal et al., 2015; Chua et al., 2014; Karthaus et al., 2014; Kwon et al., 2016) . Despite these efforts, the identity of CR prostate cells in vivo, particularly CR luminal cells, and their contribution to CRPC remain largely unresolved. To address these, we utilized a Fluidigm multiplex qPCR-based single-cell expression analysis platform to interrogate expression profiles of individual prostate cells sorted from hormone-naive (HN) and castrated mice, and coupled the analysis with organoid culture and in situ lineage tracing. With this multidisciplinary approach, here we report the heterogeneity within the luminal lineage, and identification of LY6D as a progenitor marker that is linked to CR luminal cells and CRPC.
RESULTS
Heterogeneity within the Prostate Luminal Lineage
Using a Fluidigm multiplex qPCR-based approach , we interrogated expression levels of $300 genes, including most CD (cluster of differentiation) markers, as well as prostate-related genes (Table S1 ), in individual prostate cells sorted from HN or castrated mice ( Figure 1A ). Our goal was to identify prostate epithelial subpopulations intrinsically resistant to androgen deprivation based on profiling of cell surface markers. To isolate single prostate cells, we utilized fluorescence-activated cell sorting (FACS) based on cell surface profiles of lineage markers (Lin, including CD45, CD31, TER119), SCA1, and CD49f, which separates prostate cells into the three subpopulations (referred to as ''LSC subpopulations '') Figure 1B ). Of note, several studies have observed high levels of SCA1 expression in proximal luminal cells (Korsten et al., 2009; Leong et al., 2008) . Furthermore, a recent study described a similar subpopulation of FACS-sorted SCA1-high cells, which are localized in the proximal prostatic ducts and represent an androgen-independent subpopulation of LPs Figure S1D ). The percentages of K5 + K8 + cells we detected in prostate subpopulations, sorted from both HN and CR mice, were higher (5%-20%) than those identified by IHC in situ (<5% of prostate cells) (Ousset et al., 2012; Wang et al., 2013) , which may be due to single-cell isolation process or sensitiveness of different antibody-staining techniques. The presence of K5/K8 doublepositive prostate cells was unlikely due to a sorting artifact from cell doublets, as our sorting strategy and assessment by microscopy assured that the majority of sorted cells were single cells ( Figures S1E-S1H) .
Upon confirming individual cell sorting from the SCA1 Figure 1D ; Table S2 ). In support of this conclusion, we noticed that most single cells clustered into these two groups were originally sorted from the SCA1 low/À and high and SCA1 int gates ( Figure 1D ), which are enriched with K8 + luminal and K5 + basal cells ( Figure 1C ), respectively. In addition, we observed a small number of cells, largely from the SCA1 high gate, that expressed high levels of stromal cell marker genes such as Vimentin (Vim) (Lawson et al., 2010) and Cd34 , but very low levels of Keratin genes ( Figure 1D ). Since the SCA1 high gate is in close proximity to the stromal cell gate ( Figure 1B ), these cells were probably ''contaminating'' stromal cells (which also express SCA1 highly) sorted as SCA1 high cells, although we cannot fully exclude the possibility that these were epithelial cells undergoing mesenchymal differentiation. By unsupervised clustering, we observed that prostate epithelial cells within the luminal lineage appeared more heterogeneous than those in the basal lineage ( Figure 1D ). To understand prostate epithelial cell heterogeneity pre-existing in HN mice, we first focused on the expression data of HN single cells (Figure S1I) . We found that cells of the luminal lineage (i.e., Krt8 high )
from HN mice could be separated into at least five subsets (Figure 1E) . Krt8 high -subset I, characterized by mRNA expression of Pbsn and Nkx3-1 at the highest levels, likely represents terminally differentiated luminal cells. Krt8 high -subsets III and V both exhibit expression of prostate stem/progenitor marker genes (i.e., Sca1/Ly6a [Xin et al., 2005] , Trop2/Tacstd2 [Goldstein et al., 2008] , Cd166/Alcam [Jiao et al., 2012] ); they may denote distinct subpopulations of multipotent or unipotent LPs, as some cells within Krt8 high -subset III express basal genes (e.g., , Trp63) , whereas all cells within Krt8 high -subset V express Kit (encoding C-KIT), an established marker of prostate stem/ progenitor cells (Leong et al., 2008) . We identified expression of the lymphocyte antigen 6 complex, locus D gene (Ly6d, encoding a cell surface marker that has not been implicated in prostate biology) specifically in Krt8 high -subsets III and V, raising a possibility for Ly6d as a potential marker for prostate stem/progenitor cells. Of note, the marker Ly6d, as well as the majority of known prostate stem/progenitor marker genes, are within a bilineage gene set that is expressed at medium or high levels in many basal cells and a subset of luminal cells (e.g., Krt8 high -subsets III and V) ( Figures 1D and 1E ).
Krt5
CR Luminal Cells Exhibit Bi-lineage Expression Pattern
In light of heterogeneity within the luminal lineage, we hypothesized that any similarity of single-cell signatures between HN and CR cells might form a foundation for an in silico strategy to identify one or more pre-existing prostate subpopulations(s) intrinsically resistant to androgen deprivation. To test this hypothesis, we mapped the lineage relationship between HN and CR prostate cells (i.e., cells with similar expression signatures) using SPADE (spanning-tree progression analysis of density-normalized events) analysis, a method originally developed Table S2 . (E) Enlarged view of select genes from the heatmap in Figure S1I clustering prostate cells in the luminal lineage from HN mice into five subsets. Color scale is indicated. See also Figure S1 .
to extract cellular hierarchy from high-dimensional mass cytometry data Qiu et al., 2011) . We adapted this approach recently to analyze high-dimensional qPCR data by using a dimension reduction strategy and applied it here. We first reduced data dimensions from $300 genes to 23 gene sets with similar expression patterns (Table  S3) , followed by redundancy removal by extracting the average value of each gene set. We subjected this reduced gene expression data to the SPADE algorithm to distill the 23 dimensional single-cell data down to an undirected, acyclic graph (assignment of each single cell to a cell cluster in Table S4 ) that assesses the relationship between different prostate cell subpopulations. Different cell lineages are readily separated into distinct branches ( Figure 2A Figure 2B ). Last, although cell cluster #10 positioned closest to basal cell clusters #7 and #8 (Figure 2A ), CR and HN cells in this cluster often expressed both basal (e.g., Krt5, Trp63) and luminal genes (e.g., Krt8, Cd24a) at high levels (Figures 2B and S2A) , raising a possibility that they represent basal cells committed to the luminal lineage (Rane et al., 2014; Uzgare et al., 2004; Wang et al., 2013; Xin et al., 2007) . Overall, our data reveal that CR prostate cells in both the basal and luminal lineages remain heterogeneous; among them, most CR luminal-lineage cells exhibit a bi-lineage gene expression profile at varying degrees ( Figures 1D and 2B) . Notably, this CR expression pattern includes high-level expression of multiple prostate stem/progenitor genes and the Ar gene.
LY6D Marks Subsets of Prostate Basal and Luminal Cells
Changes in the expression pattern of each gene in CR versus HN luminal cells at the single-cell level could reflect enrichment (or loss) of a pre-existing HN subset expressing that gene upon castration, and/or upregulation or downregulation of that gene in response to castration. We reasoned that if we could identify a cell surface marker that is widely expressed in CR luminal cells, but only expressed in a subset of HN luminal cells (with expression level comparable to that of CR luminal cells), we might be able to define intrinsically CR luminal cells and meanwhile provide support to the notion of pre-existing CR cells.
We analyzed the single-cell dataset, focusing on cells sorted from the SCA1 low/À gate (i.e., luminal cells) and marker genes that are expressed in the candidate LP subsets ( Figure 1E ). Although many of the previously defined prostate stem/progenitor cell-related genes exhibited upregulation in CR luminal cells, they were widely expressed in HN luminal cells (e.g., Trop2, Cd166, Cd133, Cd49f; Figure S2B ); others exhibited either no expression change (e.g., Sca1; Figure S2C ) or downregulation (e.g., Kit, Nkx3.1; Figure S2D ) in CR luminal cells compared to HN luminal cells. However, one of these genes, Ly6d, exhibited upregulation in CR luminal cells and was only expressed in a subset of HN luminal cells ( Figure S2E ). Of note, Ly6d has a human ortholog, whereas its close family member Sca1/Ly6a does not, thus providing a potential opportunity for clinical translation. Therefore, we focused subsequent analysis on this marker. (Figures 3B and S3A) . Next, we examined the relation of LY6D to other prostate cell surface markers. We found that LY6D exhibited the largest overlapping staining pattern with TROP2 (i.e., most LY6D + cells were TROP2 + and vice versa), followed by SCA1 and CD166; LY6D staining had the least overlap with CD133 ( Figures 3C, 3D , S3B, and S3C).
To further assess whether LY6D + and LY6D À subpopulations, in particular those within the SCA1 low/À luminal gate, represent separate entities, we performed gene expression profiling, by both RNA sequencing (RNA-seq) and microarray, on sorted LY6D + and LY6D À subsets from the SCA1 high , SCA1 int , and SCA1 low/À gates, respectively. By principal-component analysis (PCA), we found that the LY6D + cells from all 3 subsets clustered together and separated from the LY6D À subsets ( Figure 3E ).
Moreover, the LY6D + subsets from the SCA1 high and SCA1 (Chua et al., 2014; Gao et al., 2014; Karthaus et al., 2014) . We found that sorted LY6D + cells formed organoids with distinct morphologies, unrelated to the expression level of SCA1. The resulting organoids exhibited a morphology of solid multilayer mass ( Figure 4A , 50-100 mm), or acinar morphology (>100 mm) composed of a lumen surrounded by multiple layers, or translucent appearance (>100 mm) with a large and hollow lumen surrounded by a thin layer of cells resembling prostate ducts (Figures 4A and S4 high subpopulation exhibited by far the highest organoid-forming efficiency ( Figure 4D ). Of note, within the SCA1 high and SCA1 low/À luminal-enriched subpopulations, almost all cells with organoid-forming ability were derived from the LY6D + subset ( Figure 4D ). Organoid formation was maintained for at least three passages ( Figure S4D ). Moreover, the SCA1 high and low/À subpopulations formed increasing numbers of organoids with large lumen or translucent appearance over serial passages, suggesting an enrichment of multipotent organoids under this culture condition ( Figure S4E ).
To assess androgen dependency of organoid formation from LY6D + prostate epithelial cells, we cultured the sorted cells in the presence or absence of dihydrotestosterone (DHT) (Figure 4E) . Strikingly, we found that LY6D + cells from all three LSC gates formed organoids in an androgen-independent manner. Of note, LY6D + prostate cells from the SCA1 low/À and SCA1 int gates formed significantly more organoids in the absence of DHT, compared to LY6D À subpopulations counterparts ( Figure 4F ). Moreover, the LY6D + SCA1 high and low/À subpopulations formed increasing numbers of multipotent organoids that expanded under androgen deprivation ( Figure 4G ). S3D , and S3E). This observation suggests that the organoid culture condition, which favors growth of stem/progenitor cells, may also trigger expression of stem/progenitor marker genes (e.g., LY6D), as described previously for other stem/progenitor marker genes (e.g., SCA1 and TROP2) (Goldstein et al., 2008; Kwon et al., 2016 Figure 2B ), the relative frequencies of LY6D + cells were increased in prostates from castrated mice compared to those from HN mice ( Figures 5A and 5B) . Importantly, the absolute numbers of the total LY6D + prostate cells from castrated mice remained largely unchanged compared to those from HN mice, indeed suggesting the presence of an intrinsically CR stem/progenitor cell population ( Figure 5C ). Co-IF staining of prostate sections from castrated mice revealed the presence of K8 + CR prostate cells that were also positive for both LY6D and K5. Similarly, such LY6D See also Figure S3 . ) derived organoids from castrated mice. Organoids were cultured in the absence of DHT for 14 days, and then stimulated for 7 days with 100 nM DHT. n = 3 for each sorted subpopulation. p value: * p < 0.05. n.s., non-significant. Error bars represent mean ± SEM. See also Figures S3 and S4. ( Figure S5A ). To determine whether LY6D + prostate cells in the luminal lineage possess stem/progenitor cell activity in vivo, we utilized a genetic marking approach to label the K8 + prostate luminal lineage and correlate luminal-lineage cells with LY6D expression ( Figure 5D ). For this, K8-CreER mice (Van Keymeulen et al., 2011) Figure 5D ). Upon tamoxifen, we found that YFP + prostate epithelial cells from both HN and castrated mice were K8 + luminal, but not (Figures 5F and S5E ), but abundant in proximal regions with high-level expression of nuclear AR ( Figure S5D ; compared to rare AR + YFP + LY6D + cells in the distal region, Figure S5E ). YFP + LY6D + luminal cells dramatically increased after castration both in proximal and distal regions ( Figure 5F ) and exhibited cytoplasmic AR expression ( Figure S5E) Figure S5H) .
Collectively, our data show that LY6D is a marker of LP cells, which are intrinsically CR and possess prostate regenerative capacity. Figure 6A ). PCa initiation and progression in all induced K8-CreER;Pten L/L males was tracked by immunostaining for phosphorylated AKT (pAKT), as pAKT can be detected in Ptennull cells even before the onset of prostatic intraepithelial neoplasia (PIN) lesions ( Figure S6A ) (Shappell et al., 2004 (Ittmann et al., 2013; Park et al., 2002) , which were largely LY6D + ( Figure 6B ). Co-IF staining showed that the majority of these LY6D + cells were indeed K8 + ( Figure S6B) (Ittmann et al., 2013; Park et al., 2002; Shappell et al., 2004) lesions ( Figure 6B ). Co-IF staining showed that the majority of these LY6D + cells were K8 + , with a smaller subset of K8/K5 double-positive cells ( Figure S6B ). Such HG-PIN lesions were maintained in prostates undergoing a second round of regression (i.e., CR HG-PINs; Figure 6C ). Figure S6C ), while in the regenerated prostates of WT mice, LY6D + AR + cells were rare ( Figure S5E ).
LY6D Correlates with PCa Development from Luminal
Taken together, these findings suggest that LY6D expression correlates with PCa initiation and progression to CR growth from the luminal lineage.
LY6D Correlates with Advanced PCa in Patients
Encouraged by these results, we investigated whether LY6D expression correlates with PCa patient outcomes. First, LY6D protein expression was assessed in tissue microarrays from the Christie Hospital collection (containing 2-3 tumor cores and 1-2 normal-adjacent cores per patient). Analyses of samples from 65 patients indicated that LY6D-positive cases exhibited a trend toward worse overall survival, although statistical significance was not reached, possibly due to a small sample size ( Figures 7A, 7B , and S7A). To obtain additional evidence for correlation of LY6D expression with advanced PCa, we analyzed several publicly available genomic datasets. We first analyzed the well-annotated Memorial Sloan Kettering Cancer Center (MSKCC) (Taylor et al., 2010) and The Cancer Genome Atlas (TCGA) (Cancer Genome Atlas Research Network, 2015) cohorts and observed significant association of biochemical relapse of patients with upregulated LY6D expression ( Figure 7C ); in contrast, correlation of upregulated expression of several known stem/progenitor markers (e.g., TROP2/TACSTD2 [Goldstein et al., 2008] and CD166/ALCAM [Jiao et al., 2012] ) with patient outcomes is not significant or exhibits conflicting levels of significance between the MSKCC (Taylor et al., 2010) and TCGA (Cancer Genome Atlas Research Network, 2015) cohorts (Figure S7B ). Of note, PCa patients with high levels of LY6D showed a reduced overall survival ( Figure 7D ), despite the relatively short follow-up of PCa patients in the TCGA cohort. Moreover, an inferior clinical outcome of patients with LY6D expression was maintained when we restricted our analyses only to patients with Gleason score 7 (GS7) ( Figure S7C ). Comparative copy number analysis revealed that LY6D amplification is much more frequent in metastatic CRPC patient samples than in primary prostate tumors or non-castrated metastatic cancers, and is particularly high in CRPC metastatic patients with neuroendocrine phenotype ( Figure S7D ). Since LY6D maps $16 Mb apart from MYC in the chromosome 8q24 region, most of the cases patients showed a co-amplification of LY6D and MYC. To exclude the possibility that the association of LY6D expression with aggressive PCa is related to MYC amplifications, we examined the association of LY6D and MYC mRNA expression and disease outcomes, in the above-analyzed MSKCC and TCGA cohorts. We did not observe a correlation between MYC and LY6D mRNA expression ( Figure S7E ). In addition, comparison of patients with high to those with low MYC mRNA expression levels did not show differences in the frequency of biochemical relapses ( Figure S7F ). Moreover, we also found no correlation between MYC mRNA expression or amplifications and LY6D mRNA expressions in primary PCa tumors ( Figures S7E-S7G) , suggesting that the negative prognosis of patients with LY6D + PCa is not attributed to MYC amplifications.
Taken together, data from both animal models and patient cohort analyses suggest that LY6D + luminal cells are intrinsically androgen-resistant and possess stem/progenitor cell properties, features that may contribute significantly to prostate carcinogenesis. Furthermore, LY6D may be used as a prognostic marker of aggressive disease and disease recurrence, and may serve as a predictive marker for development of CRPC. 
DISCUSSION
Our single-cell expression analysis reveals molecular heterogeneity in the prostate luminal and, to a lesser degree, basal lineages. We found that a subset of prostate cells in the luminal lineage co-express multiple basal (e.g., Krt5, Krt14, Trp63) and luminal (e.g., Krt8, Krt18, and Ar) markers together with prostate stem/progenitor marker genes (e.g., Ly6d, Trop2, Sca1, Cd133, Cd166) . Many of these stem/progenitor genes are found within a bi-lineage gene set expressed in both basal cells and a portion of luminal cells. Intermediate prostate cells have been associated with luminal differentiation of basal cells (Ousset et al., 2012; Wang et al., 2009 Wang et al., , 2013 derived from LY6D + subpopulations, although we cannot entirely rule out the possibility that differentiated progenitors derived from those multipotent cells temporally maintain the expression of LY6D.
Our in vitro and in vivo data also support that LY6D + cells in the luminal lineage represent multipotent and/or unipotent LPs inherently resistant to androgen deprivation and with regenerative capacity. We found that LY6D + prostate cells from the SCA1 high and SCA1 low/À gates were enriched with organoidforming multipotent LPs and formed increasing numbers of multipotent organoids in the absence of androgen, which has been further validated using organoid outgrowth of luminal YFP + LY6D + cells. In addition, CR LY6D + cell-derived organoids underwent nuclear AR localization and luminal differentiation upon androgen stimulation. Consistent with our observations, it was reported that a label-retaining AR + progenitor population that expresses multiple prostate stem/progenitor markers was present in the castrated prostate and exhibited sign of expansion following castration (Shi et al., 2014) . However, we also cannot entirely exclude the possibility that luminal cells can also adapt to castration and subsequently upregulate expression of some of the stem/progenitor genes (e.g., Ly6d) . LY6D is a gene with no established role in prostate development or cancer. It is a member of the Ly6/uPAR family characterized by their roles in cell proliferation, cell-cell interaction, immune cell maturation, and cytokine production, which are all essential components of tumor initiation and progression (Loughner et al., 2016) . Under physiological conditions, LY6D has been used as a marker of early B cell specification (Inlay et al., 2009) , although its role in B cell development is unclear. In malignancies, however, LY6D expression is induced on the surface of various cancer cells after genotoxic stress, which was proposed as a marker to stratify patients with increased risk for developing distant metastases (Kurosawa et al., 2012; Rubinfeld et al., 2006) . Consistent with this notion, a recent study revealed positive correlations of increased expression of multiple Ly6 family members, including LY6D, with poor patient outcomes in multiple cancer types . LY6D plays an important role in adhesion of head and neck cancer cells to endothelial cells, which is essential during the metastatic extravasion process (Eshel et al., 2002) . Disruption of its closely related members (i.e., LY6E/K) in human breast cancer cell lines has been reported to modulate transforming growth factor b (TGF-b) signaling (AlHossiny et al., 2016) . However, in PCa, the functional role of LY6D for tumorigenesis and tumor maintenance, if any, remains unknown and awaits further investigations.
A major challenge in the management of patients with PCa is the distinction of indolent from aggressive disease. Hence, markers to predict clinical outcomes are urgently needed. Human LY6D is located on chromosome 8q24, a region that is frequently amplified in PCa and contains numerous risk loci (Brakenhoff et al., 1995; Nakagawa et al., 2012) . Analysis of human PCa cohorts revealed that higher LY6D expression levels, after removing cases with MYC amplification or potential MYC overexpression (due to close distance between these two genes and amplification of this genomic region), appeared to be associated with more aggressive disease and worse outcomes, suggesting that LY6D may serve as a prognostic biomarker for advanced PCa. Further studies are warranted to determine the precise role of LY6D in prostate epithelial heterogeneity, PCa initiation, and progression to adenocarcinoma, to validate its utility as a biomarker for patient stratification and to assess the impact of CR LY6D + cells as therapeutic targets for patients with lethal PCa.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Esther Baena (esther.baena@cruk.manchester.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animal models
For animal studies, K8-CreER transgenic mouse (Van Keymeulen et al., 2011) , R26Y reporter mouse (C57BL/6) (Srinivas et al., 2001) , and Pten conditional knockout mouse (Pten L/L ) (C57BL/6) (Lesche et al., 2002) 
Organoid-formation assay
In vitro organoids formation were performed as described below [and also reported in (Chua et al., 2014; Karthaus et al., 2014) ]. Mouse prostate single cells suspensions were isolated by digestion of mouse prostate with collagenase/dispase (1mg ml -1 ) for 1h at 37 C. Single cells suspensions were embedded in growth factor reduced Matrigel (Corning/BD, 354230) or BME-2 (AMSBIO, 3533-010-02) and plated a 40 mL drop/well (1,000-3,000 cells/drop) in the center of 96-well optical bottom plates. Organoid culture medium was composed of ADMEM/F12 medium with B27 (Life Technologies, 17504-044), 50mg ml -1 EGF (PeproTech, AF-100-15), 500ng ml -1 recombinant R-spondin 1 (R&D Systems, 4645-RS-025), 100ng ml -1 Noggin (PeproTech, 120-10C), 10mM Y-27632 dyhydrochloride (Sigma-Aldrich, Y0503), 200nM A83-01 (Tocris Bioscience, 2939) and plus/minus 1nM Dihydrotestosterone (DHT, Sigma 730637); as described in (Chua et al., 2014; Karthaus et al., 2014) ); the medium was changed once every 4 days and organoids outgrowths were counted with a Zeiss Axiovert 200M inverted microscope at 10X magnification approximately 7-9 days post-seeding. Organoids were measured using AxioVision 4.9 image acquisition software. Cells from organoids used for serial passages were recovered from Matrigel or BME2 with Cell Recovery Solution (Corning, 354253), dissociated into single cells with TrypLE (Life technologies, 12563011), and replated. Murine prostates of hormone-naive and castrated mice were dissected and dissociated into prostate single cells and FACS sorted for epithelial LY6D +/À SCA1 high or int or low/-subpopulations. For regeneration assays, each sorted subpopulation from HN or castrated mice was seeded in the absence of DHT for 14 days, then the growing media was supplemented with DHT (100nM) for up to 7 days. Organoids were imaged and counted at day 7 and 14 organoids under androgen-deprived conditions, as described above. Experimental endpoint was 7 days after adding DHT to the media, when organoids were imaged and fixed. Prostate regeneration assay Prostate regeneration assay was performed as previously described (Lukacs et al., 2010) . Briefly, after FACS, the sorted YFP + LY6D + or -luminal cells were seeded in PrEGM (Lonza, Cat# CC-3165) with Matrigel for 9-10 days. Cells were then collected, and approximately 2.5 3 10 5 cells were mixed with 2.5 3 10 5 Urogenital sinus mesenchyme (UGSM) cells and subcutaneously injected with Matrigel into flanks of Rag2 À/À mice. Outgrowths were collected 8 weeks post implantation.
METHOD DETAILS IF and IHC staining and histology
Cryosections of prostate tissues were cut at 8mm, blocked in 2.5% goat serum, and incubated with primary antibodies overnight at 4 C. The Matrigel drops containing organoids were embedded in histogel (Thermo Scientific, Richard-Allan Scientific HistoGel) or suspended in PBS as previously described (Broutier et al., 2016) . They were then fixed in 4% PFA overnight at 4 C, and embedded in paraffin following standard protocols. For frozen sections, organoids were fixed in 2% PFA for 20min at room temperature, washed in PBS, and saturated in 30% sucrose overnight at 4 C. Tissues were then embedded in OCT compound (Sakura) and stored at À80 C prior to cryosectioning. FFPE-or cryo-sections (5 mm) were subsequently used for IF and IHC staining. Antibodies were used to detect Keratin 5 (K5, Covance PRB-160P; Abcam # ab193895), Keratin 8 (K8, Covance MMS-162P; Abcam ab194130; Abcam # ab193895), YFP (Abcam 13970), LY6D (BD 557360), AR (Santa Cruz sc-816), KI67 (IHC-00375, Bethyl Laboratories), p63 (Millipore clone4A4 MAB4135) or pAKT (Cell Signaling 4060). Alexa Fluor-conjugated secondary antibodies (Life Technologies) were incubated for 1 hr at room temperature. Nuclei were counterstained with DAPI and slides were sealed with Vectashield mounting media (Vector). A similar IF staining procedure was also performed for FACS-sorted cells cytospin onto glass slides. For multiplexed staining, the Opal protocol (Perkin Elmer, NEL794001KT) was used following the manufacturers' instructions. Briefly, the slides were deparaffinized in xylene and rehydrated in ethanol. Antigen retrieval was performed in citrate buffer (pH 6.0) in microwave oven. Primary rabbit antibodies for K5 (1:1000) were incubated for 1 h in a humidified chamber at room temperature, followed by detection using the rabbit Detection HRP kit. Visualization of K5 was accomplished using fluorescein TSA Plus (1:50). In serial fashion, the slides were then retrieved in citrate buffer (pH 6.0) and then incubated with primary antibodies for K8 (1:1000), and Ki67 (1:1000). The in situ hybridization to detect Ly6d (RNAscope probe Ms-Ly6d, ACD #532071) was done following the manufacturers' instructions. Briefly, FFPE sections were deparaffinized in xylene and rehydrated in ethanol, then incubated with protease K for 15min. The sections were then washed, and hybridized with the Ly6d probe followed by immunostaining with K8 antibody (1/200, ab53280) for 1h at room temperature. Cryosections used for histological examination (H&E stained) and IHC staining were mounted in Permount mounting media (Fisher). Quantification of IF staining was performed by ImageJ software (NIH Image, Maryland, USA).
For whole-mount IF staining, organoids were dissociated from the 3D matrix (Matrigel or BME 2) and fixed with PFA 4% for 20 min on ice. After washing in PBS, organoids were permeabilized with PBS-T (0.4% Triton X-100 in PBS) for 15 min and blocked using 10% goat serum (Goat serum, DAKO #X0907) for 1h at room temperature. Primary antibodies staining for K5 (1/100, ab193895), K8 (1/100, ab192467) and LY6D (1/100) was performed by overnight incubation at 4 C. Next day organoids were washed and incubated with the fluorescently labeled secondary antibody for 2-4 hr at room temperature. Nuclei were counterstained with DAPI (2 mg/ml, Sigma #D9542-10MG). IF images were acquired using high content screening system Opera Phenix (Perkin Elmer) and evaluated with the Columbus Image Analysis system. FACS cell sorting FACS analyses and sorting were performed as described in (Lukacs et al., 2010) . Mouse prostate single cells suspensions were isolated by digestion of mouse prostate with collagenase/dispase (1mg ml -1 ) for 1 hr at 37 C followed by 0.25% Tripsin/EDTA (2min at 37 C) and Dispase/DNaseI (5mg/ml Dispase, 1U/mL DNase, incubation for 5min at 37 C) treatments. Dissociated prostate epithelial cells were stained with specified fluorochrome-labeled antibodies (eBioscience) for 15 min on ice, washed, filtered (0.50mm cell strainer, Corning) and analyzed and/or sorted using BD FACS Aria II/III flow cytometers. FACS analysis was performed using FlowJo CE software. Sorting based on DAPI, Lineage (Lin: CD31, CD45, TER119), SCA1, and CD49f was used to separate viable prostate epithelial cells from stromal cells (Goldstein et al., 2008; Lawson et al., 2007) . Intracellular K5 and K8 analysis were performed as previously described in . Briefly, following staining with cell surface markers, prostate cells were fixed with 1% PFA, permeabilised (BD Perm/Wash buffer, BD Biosciences #554723), incubated with K5-AF645 (Abcam, #ab52635) or K8-AF488 (Abcam, ab53280) for 30min on ice, washed and analyzed using BD Fortessa. DAPI (Life Technologies, D3571) was used for cell viability. Antibodies used for FACS were purchased from eBiosciences (San Diego, CA) and included SCA1-PE (12-5981), SCA1-PE-Cy7 (25-5981), CD49f-APC (17-0495), LY6D-PE (12-5974), CD133-FITC (11-1331), CD24-FITC (11-0242) or CD166-PE (12-1668). SCA1-APC-Cy7 (108126) was purchased from Biolegend (San Diego, CA). Biotinylated or e-Fluor-450 conjugated CD31, CD45, TER119 (13-0311/48-0311, 13-0451/48-0451, 13-5921/48-5921) or biotinylated TROP2 (R&D BAF1122) were also used in combination with streptavidin-PE Cy7 (25-4317), -APC (17-4317) or -eFluor 450 (48-4317).
We selected epithelial regions by Keratin staining in each core and scored the LY6D positive cells, using anti-human LY6D antibody (Sigma, HPA 024755). We used the Manchester Cancer Research Centre (MCRC) archival diagnostic prostate tissue collection from PCa patients collected within the Salford NHS Foundation Trust with informed subject consent for construction of tissue microarrays [built by the Genito-Urinary cancer research group at the Christie Hospital (Manchester, UK)], and under the approval from the MCRC Biobank Review Board (10_NOCL_02; #14_ESBA_01). Tissue microarray slides were scanned with the Mirax automated imaging system (Zeiss) using a 20x magnification objective and the image analysis and quantification was performed using Definiens Tissue Phenomics Software. This is a software program for the automated image analysis of tissue samples. We evaluated immunostaining blinded to clinicopathological information and scored the cores as negative (0), or positive (1). We used univariate Cox regression analysis (R packages: 'survminer' and 'survival') to assess the ability of LY6D expression to predict overall survival after radical prostatectomy/diagnosis.
QUANTIFICATION AND STATISTICAL ANALYSIS
Continuous data are reported as mean ± SEM. Categorical data are reported as frequencies and percentages. Categorical data were evaluated using chi-square test. Comparison of disease free survival and overall survival between groups was done using KaplanMeier method and log-rank test. Student's t test was used to compare means between two groups. Statistical significance was set at p < 0.05. Data for evaluating pathological features was downloaded from cBioportal (http://www.cbioportal.org/). Disease free survival and overall survival for Taylor and TCGA cohorts were evaluated online on cBioportal. Statistical analysis was done using IBM SPSS version 23 (IBM corp., Armonk, New York, USA) unless stated otherwise. For LY6D expression Kaplan-Meier analysis, the optimal z-score cut-off was calculated using the R2: genomics analysis and visualization platform (https://hgserver1.amc.nl:443/) in the TCGA cohort, and independently validated the same z-score (> 1.3) cut-off in the MSKCC cohort. For animal model studies, no statistical method was used to pre-determine the sample size for mice. No randomization or blinding was used in the in vivo studies.
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